Adiponectin, via AdipoR1, inhibits mTOR through AMPK activation in renal cell carcinoma (RCC), suppresses vascular endothelial growth factor (VEGF), MMP-2 and MMP-9 and increases TIMP-1 and TIMP-2 secretion, resulting in decreased growth, dissemination and angiogenesis of RCC [94]. This evidence concerns the gene MMP9 and renal cell carcinoma.